当前位置: X-MOL 学术Cell cycle › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Coronavirus disease 2019 (COVID-19), human erythrocytes and the PKC-alpha/-beta inhibitor chelerythrine –possible therapeutic implication
Cell Cycle ( IF 3.4 ) Pub Date : 2020-12-11 , DOI: 10.1080/15384101.2020.1859197
Mehrdad Ghashghaeinia 1, 2 , Peter Dreischer 2 , Thomas Wieder 2 , Martin Köberle 3
Affiliation  

ABSTRACT

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19. Until now, diverse drugs have been used for the treatment of COVID-19. These drugs are associated with severe side effects, e.g. induction of erythrocyte death, named eryptosis. This massively affects the oxygen (O2) supply of the organism. Therefore, three elementary aspects should be considered simultaneously: (1) a potential drug should directly attack the virus, (2) eliminate virus-infected host cells and (3) preserve erythrocyte survival and functionality. It is known that PKC-α inhibition enhances the vitality of human erythrocytes, while it dose-dependently activates the apoptosis machinery in nucleated cells. Thus, the use of chelerythrine as a specific PKC-alpha and -beta (PKC-α/-β) inhibitor should be a promising approach to treat people infected with SARS-CoV-2.



中文翻译:

2019年冠状病毒病(COVID-19),人红细胞和PKC-α/β抑制剂白屈菜红碱–可能的治疗意义

摘要

严重的急性呼吸综合症冠状病毒2(SARS-CoV-2)导致COVID-19。迄今为止,已经使用了多种药物来治疗COVID-19。这些药物与严重的副作用有关,例如诱导红细胞死亡,称为隐匿性。这会严重影响氧气(O 2)生物体的供应。因此,应同时考虑三个基本方面:(1)潜在的药物应直接攻击病毒;(2)消除感染了病毒的宿主细胞;(3)保留红细胞的存活和功能。已知PKC-α抑制可增强人红细胞的活力,而剂量依赖性地激活有核细胞中的凋亡机制。因此,白屈菜红碱作为一种特定的PKC-α和-β(PKC-α/-β)抑制剂的使用应该是治疗感染SARS-CoV-2的人的有前途的方法。

更新日期:2020-12-31
down
wechat
bug